ORM2: Orosomucoid 2
A key acute-phase plasma protein with roles in inflammation and immunomodulation
Gene Information Card
| Symbol | ORM2 |
|---|---|
| Full Name | Orosomucoid 2 |
| Gene Type | protein-coding |
| Chromosomal Location | 9q32 |
| NCBI Gene ID | 5005 ncbi.nlm.nih.gov/gene/5005 |
| Ensembl ID | ENSG00000107175 |
| UniProt ID | P19652 |
| OMIM ID | 138600 |
| HGNC ID | 8498 |
| Aliases | AGP2, AGP-B, AGP-B' |
Description
ORM2 (orosomucoid 2) encodes a member of the lipocalin family, orosomucoid 2 (also known as alpha-1-acid glycoprotein 2, AGP2). This protein is a major acute-phase plasma glycoprotein synthesized primarily in the liver. It functions as a carrier protein for basic and neutral lipophilic drugs and plays roles in immunomodulation, inflammation, and maintaining capillary permeability. ORM2 is one of two highly similar orosomucoid genes (ORM1 and ORM2) located in a cluster on chromosome 9q32.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Acute-phase response | ORM2 is upregulated during inflammation as part of the acute-phase reaction, contributing to immunomodulation and drug binding. | NCBI Gene, UniProt |
| Cancer (various) | Altered ORM2 expression has been reported in several cancers, potentially affecting drug bioavailability and immune response. | COSMIC, PubMed |
| Inflammatory disorders | Elevated plasma ORM2 levels are associated with chronic inflammatory conditions such as rheumatoid arthritis. | UniProt, PubMed |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Liver | 215.3 | High |
| Plasma | N/A | High (secreted) |
| Adipose tissue | 1.2 | Low |
| Lung | 0.8 | Low |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| HepG2 | 12.5 | Hepatocellular carcinoma cell line |
| Huh-7 | 10.1 | Hepatoma cell line |
| A549 | 0.3 | Lung carcinoma cell line |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.1A>G | SNV | <0.01% | Likely benign; no known functional impact |
| c.123C>T | Missense | <0.01% | Uncertain significance |
Mutation functional classification
Loss of Function (LOF)
No well-characterized loss-of-function mutations reported in ORM2.
Gain of Function (GOF)
No gain-of-function mutations described.
Dominant Negative (DN)
Not applicable.
View complete mutation data：
Gene Ontology (GO)
Pathways
• Acute phase response signaling (Reactome: R-HSA-6783783)
• Lipocalin/cytokine pathway
Protein Summary
Orosomucoid 2 (ORM2) is a 201-amino-acid glycoprotein (UniProt P19652) with a molecular weight of approximately 23.6 kDa (unglycosylated). It is heavily glycosylated, contributing to its heterogeneity. The protein adopts a typical lipocalin fold with a beta-barrel structure that forms a hydrophobic ligand-binding pocket. ORM2 binds various drugs (e.g., propranolol, imatinib) and endogenous ligands (e.g., steroids, bilirubin). It is primarily synthesized in hepatocytes and secreted into plasma, where it constitutes about 1-3% of total plasma proteins. Its expression is upregulated by interleukin-1, interleukin-6, and glucocorticoids during the acute-phase response.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| ORM2 Knockout HEK293 Cell Line | EDJ-KQ50496 | Human | 5005 | Details Get a Quote |
| ORM2 Knockout HeLa Cell Line | EDJ-KQ54059 | Human | 5005 | Details Get a Quote |
| ORM2 Knockout A-549 Cell Line | EDJ-KQ62547 | Human | 5005 | Details Get a Quote |
| ORM2 Knockout HCT 116 Cell Line | EDJ-KQ71019 | Human | 5005 | Details Get a Quote |
Displaying Records 1 To 4 Of 4 Records
